LifeStance Health Group, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless otherwise noted. LifeStance provides outpatient mental health services through its subsidiaries and supported practices. It reported 6,866 clinicians and approximately 1.9 million patient visits during the quarter. Dollar amounts below are in millions unless stated otherwise.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change / context |
|---|---|---|---|
| Revenue | $300.4 | $252.6 | Up 19% |
| Operating expenses | $317.2 | $286.7 | Up 11% |
| Loss from operations | $(16.8) | $(34.1) | Operating margin improved to approximately (5.6)% from (13.5)% |
| Net loss | $(21.1) | $(34.2) | Net loss per share was $(0.06), versus $(0.09) |
| Adjusted EBITDA | $27.7 | $10.1 | Non-GAAP measure; see filing’s reconciliation and exclusions |
| Center Margin | $94.7 | $69.6 | Non-GAAP measure; approximately 31.5% of revenue versus 27.5% |
| Cash used in operating activities | $(21.8) | $(7.9) | Greater cash use, including a substantial accounts receivable increase |
Revenue growth was primarily attributed to a net increase of 905 clinicians and 0.2 million more visits, up 15%; management also cited higher revenue per visit, primarily from payor rate increases. Commercial payors represented 91% of revenue. Two individual commercial payors accounted for 17% and 15% of revenue, respectively.
Financial position and liquidity
- Cash and cash equivalents were $49.5 at March 31, 2024, down from $78.8 at December 31, 2023. Patient accounts receivable rose to $175.9 from $125.4.
- Total assets were $2,106.3; total liabilities were $677.3. Current assets of $244.1 compared with current liabilities of $207.5.
- Debt principal outstanding was $288.8, compared with $289.5 at year-end; net carrying value was $279.9. No revolving credit facility borrowings were outstanding. The company was in compliance with debt covenants.
- The company had $262.4 of undiscounted future minimum operating lease payments. Operating lease liabilities totaled $223.0.
- Cash declined by $29.4 overall. Investing activities used $5.1, principally for property and equipment; financing activities used $2.4, including debt and contingent consideration payments.
Material changes and management commentary
- Management attributed the lower cash balance and delayed cash receipts in part to the February 2024 Change Healthcare systems disruption, which delayed claims submissions and some payor processing. The company adopted an alternative claims clearinghouse, reported progress resuming submissions, and expected processing and remittance delays to be resolved in 2024.
- Center costs increased 12%, mainly from higher clinician compensation associated with clinician growth and increased visits. G&A increased 5%; higher salaries and benefits were partly offset by lower stock-based compensation.
- No acquisitions were completed in Q1 2024; the company acquired three practices in Q1 2023. Q1 2024 investing cash use was therefore lower than the prior-year quarter, which included acquisitions.
- Management expects continued revenue growth from clinician recruiting, de novo centers, and more visits, including virtual care. It expects center costs to increase in the short to medium term as it invests in growth. No numerical revenue or earnings guidance was provided.
- Management stated that existing cash should fund operating and capital needs for at least 12 months from issuance of the financial statements, while noting that actual needs depend on growth, spending, acquisitions, and other factors and additional financing may be required.
Risks, contingencies, and unusual items
- Disclosure controls and procedures were deemed ineffective as of March 31, 2024 because previously reported material weaknesses in internal control over financial reporting remained unremediated. Remediation efforts were ongoing; the weaknesses relate to finance and IT resources, accounting controls, and IT general controls.
- Two employment-related collective/class actions allege compensation and time-worked issues; a separate class action alleges privacy claims relating to website pixel technologies. The suits seek unspecified damages. The company recorded no material accrual and said the outcomes could not be predicted.
- The filing describes healthcare regulatory and reimbursement risks, potential payor rate reductions or coverage restrictions, clinician recruiting and retention risks, dependence on supported practices, competition, and cybersecurity and information-system risks.
- Variable-rate debt creates interest-rate exposure; a swap hedged 94.5% of the term loan previously exposed to SOFR, with a stated fixed swap rate of 3.24% and maturity in September 2025. The company said a 100-basis-point rate change would not have a material effect.
- Q1 adjusted EBITDA excludes, among other items, stock-based compensation, litigation costs, strategic initiatives, and other specified expenses. Stock-based compensation expense was $20.6; unrecognized compensation expense was $203.7.
Important facts for investors to verify
- Whether claims processing and cash collections recover as expected following the Change Healthcare disruption, and whether receivables and operating cash flow normalize.
- Whether clinician additions, visit growth, and payor rate increases continue to support revenue and center-margin improvement.
- Whether the company can fund growth and service debt and lease obligations while maintaining covenant compliance and adequate liquidity.
- Progress and testing of remediation for the material weaknesses, and whether disclosure controls become effective.
- Developments in the employment and privacy litigation, healthcare regulatory matters, and payor contract negotiations.
- The sustainability of improvement in non-GAAP Center Margin and Adjusted EBITDA relative to GAAP losses and cash use.